Ironwood Pharmaceuticals Q1 2022 Earnings Report
Key Takeaways
Ironwood Pharmaceuticals reported its first quarter 2022 results, featuring an 11% year-over-year increase in LINZESS® prescription demand and U.S. LINZESS® net sales of $232 million, an 8% increase year-over-year. The company reported total revenue of $98 million, GAAP net income of $39 million, and adjusted EBITDA of $58 million, ending the quarter with $593 million in cash and cash equivalents.
LINZESS prescription demand growth increased 11% year-over-year.
LINZESS U.S. net sales reached $232 million, an increase of 8% year-over-year.
Total revenue was reported at $98 million, with U.S. LINZESS collaboration revenue of $94 million.
GAAP net income was $39 million and adjusted EBITDA was $58 million; the quarter ended with $593 million in cash and cash equivalents.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
Forward Guidance
Ironwood Pharmaceuticals maintained its full year 2022 financial guidance.